Floatz logo

vo659

Huntington Disease

Vico Therapeutics B. V.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Huntington Disease cohort.

Asset / SponsorPhaseRating
Deutetrabenazine
Teva Branded Pharmaceutical Products R&D LLC
Phase 4BBB
Tetrabenazine
William Ondo, MD
Phase 4BBB
ro7234292
Hoffmann-La Roche
Phase 3BBB
Dimebon
Medivation, Inc.
Phase 3BB
Pridopidine
Prilenia
Phase 3BB

View all 50 →

Same molecule, other indications

vo659 is also rated in:

spinocerebellar ataxia type 1Dormant
NR
Indicative ·
/ 100
View asset →
Machado-Joseph diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →